Cannabis Science Inc (fka CBIS)

[Vapobag]

Received a promo for you guys.

Greetings Traders,

By far this year, the biggest, most explosive sector on Wall Street has been medical marijuana. It’s been a story so far of “rush” on the part of state legislature to accommodate the legalization of the plant and by companies to get in the line towards profits. It’s been an interesting story so far and if the analysts are to be believed, the push to extract every last dollar from the projected $100B space is just getting started.

Our latest pick is an OTC QB tiered company that is engaged in the development of marijuana related drugs to helps patients best with all sorts of illness. In recent months the company has been very busy on the news front and has shown considerable upside in the very young and growing medical marijuana space.

CBIS has lauded the New York State legislature for its push towards relaxing medical marijuana laws and already is championing the move by Colorado and Washington who’d both opted for wholesale legalization.

The overall bullishness towards medical marijuana plays has helped CBIS to reach a 12-month high of .298 and volume has just been off the charts. The liquidity in this play is very inviting and relative strength is very well positioned in bounce territory – we are talking sub-40 here.

After pullbacks from the high .12s CBIS looks poised for a rebound which is why it is our immediate alert for your participation.

Complete your due diligence as soon as you can.

About CBIS

CBIS (Cannabis Science, Inc.) is a development stage company, which engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products.

CBIS primarily focuses on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance.

CBIS has a license agreement with Apothecary Genetics Investments LLC. to produce various brand formulations for California medical cannabis market.

CBIS is based in Colorado Springs, Colorado.

Top Investor Highlights
CBIS’s has been actively involved in the procurement and initiation to place treatment and scientific research for the anticipated usage of medical marijuana in New York State.
CBIS stated in a June release that it is in a strong financial position to move forward with its pre-clinical drug development.
CBIS has had a healthy past 12 months in trading. The play has reached a high of .298 and currently has very strong liquidity.
CBIS has very strong bounce/rebound potential and with a RSI of 38, a catalyst isn’t far from sight
Gov. Cuomo signs New York's medical marijuana bill into law

New York has become the 23rd state to authorize medical marijuana — though the program will be one of the most restrictive in the nation.

New York’s law, which Gov. Cuomo celebrated at a ceremonial signing Monday, prohibits smoking the drug. Marijuana will have to be ingested or administered through a vaporizer, oil base or waxes.

The state will certify up to five companies to grow and distribute the drug.

And Cuomo retains the power to halt the program if either the state health commissioner or state police superintendent recommends it.

“I wasn’t going to sign a medical marijuana bill without those protections,” Cuomo said at the ceremony at the New York Academy of Medicine in Manhattan.

Cuomo was introduced by Maryanne Hauser, whose 10-year-old daughter, Amanda, suffers from dangerous, incurable epileptic seizures caused by Dravet syndrome.

Medical marijuana would provide some relief to Amanda, because certain strains of marijuana — which will not produce a “high” — can help alleviate seizures.

“We were prepared to move out of New York State if we needed to, to get Amanda’s treatment,” Hauser said. “But now we don’t have to."

Illinois Legalizes Medical Marijuana For Children With Seizures

Illinois children and adults with epilepsy will soon be allowed to use marijuana to ease their symptoms under a law signed on Sunday by Democratic Governor Pat Quinn, the latest in a series of measures loosening restrictions on cannabis by U.S. states.

The move to add epilepsy and other seizure disorders to the list of conditions legal to treat with marijuana or its extracts comes as numerous states have made medical use of the drug legal. Two states, Colorado and Washington, have legalized its recreational use.

"This new law will help alleviate the suffering of many adults and children across the state," Quinn said in statement. "Epilepsy is a debilitating condition, and this much-needed relief will help to reduce some of its symptoms for those who endure seizures."

The Illinois law, which takes effect in January, would allow children who experience seizures to be treated with non-smokable forms of cannabis, as long as they have permission from a parent.

"I have a 14-year-old constituent by the name of Hugh who lives with epilepsy," said Republican state lawmaker Jim Durkin, who co-sponsored the new law. "His parents, Bob and Kelly, want to provide their son with as much relief as possible. Unfortunately, traditional medications and methods have not worked."
The state is putting the final touches on a broader medical marijuana plan, a tightly regulated program whose regulations were finalized just last week.

Residents will be allowed to apply for permission to use the drug to treat medical conditions in September, and the full program is expected to be up and running early next year, Quinn spokeswoman Katie Hickey said on Sunday.

In Summary

So that’s two big states that have put their power behind medical marijuana and the good news? More states are lining up to do the same.

CBIS therefore represents a unique and early-stage opportunity to get in on the medical marijuana bonanza. And besides what’s not to like about the play?

A good mix of technicals and fundamentals means that at any moment a pop (and a huge run) could occur.

Don’t fall asleep on CBIS.

Start your research now.

You can learn more about CBIS by visiting their website: http://www.cannabisscience.com/

For more information on CBIS: http://www.otcmarkets.com/stock/CBIS/quote

To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts.

Grab your cell phone and text the word "PICKS" to "33733”


Best regards,

StockMarketIntel


The disclaimer is to be read and fully understood before using our site, or joining our email list. This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockMarketIntel.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Release of Liability: Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. StockMarketIntel has been compensated up to seven thousand five hundred dollars cash by ALG Financial LLC. for a marketing and advertising effort on CBIS. These third party, may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.

StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead StockMarketIntel.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. StockMarketIntel.com is compliant with the Can Spam Act of 2003. StockMarketIntel.com does not offer such advice or analysis, and StockMarketIntel.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to FWD-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "FWD looking statements". FWD looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. FWD looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, StockMarketIntel.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, StockMarketIntel.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. StockMarketIntel.com is not responsible for any claims made by the companies advertised herein, nor is StockMarketIntel.com responsible for any other promotional firm, its program or its structure.


3411 Silverside Rd, Wilmington, DE 19810, United States
You may unsubscribe or change your contact details at any time.